摘要
贝伐珠单抗(Bevacizumab,BEV)是一种重组人源化抗血管内皮生长因子(vascular endothelial growth factor,VEGF)的单克隆抗体,通过阻断VEGF与其受体结合,抑制肿瘤新生血管形成,从而抑制肿瘤生长。临床研究表明,BEV单药治疗复发性卵巢癌的疗效确切,并且与紫杉类药物、脂质体阿霉素及环磷酰胺等药物联合使用疗效更佳。此外,BEV能有效控制恶性腹水,提高患者的生活质量。因此BEV在复发性卵巢癌的治疗中具有广阔的应用前景。
Bevacizumab(BEV), a recombinant humanized anti-VEGF monoclonal antibody, represses the tumor angiogenesis by blocking the binding of VEGF to its receptors,thus to inhibit the growth of malignancies. Clinical studies have demonstrated that BEV is active as a single agent for recurrent ovarian cancer, and exhibits better efficacy when combines with cytotoxic drugs, such as taxane, pegylated liposomal doxorubicin, cyclophosphamide and so on. Moreover, BEV plays an important role in the management of malignant ascites caused by ovarian cancer and significantly improves the patients' quality of life. Therefore, BEV has broad prospects in the treatment of recurrent ovarian cancer.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2015年第4期416-420,共5页
Cancer Research on Prevention and Treatment
关键词
贝伐珠单抗
血管内皮生长因子
复发性卵巢癌
恶性腹水
Bevacizumab(BEV)
Vascular endothelial growth factor(VEGF)
Recurrent ovarian cancer
Malignant ascites
